Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
about
Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerizationRelationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicitySynphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synucleinThe H50Q mutation enhances α-synuclein aggregation, secretion, and toxicityAlpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recyclingPre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease modelsα-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formationNative α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functionsPhysicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)Genetically engineered mouse models of Parkinson's diseaseFunction and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescencen-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseMicrotubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filamentsThe role of α-synuclein and tau hyperphosphorylation-mediated autophagy and apoptosis in lead-induced learning and memory injuryGamma-synuclein as a marker of retinal ganglion cellsAcyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolismAltered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathiesSolid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-SynucleinBiophysics of α-synuclein membrane interactions.Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration.Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiaeDynamic transport and localization of alpha-synuclein in primary hippocampal neurons.Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbensα-Synuclein-induced tubule formation in lipid bilayersModelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomersBiophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast.Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopyThe clustering and spatial arrangement of beta-sheet sequence, but not order, govern alpha-synuclein fibrillogenesisAlpha-synuclein in Lewy body disease and Alzheimer's disease.Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behaviorMembrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations.alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Late-onset neurodegenerative diseases--the role of protein insolubility.The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms.Familial conformational diseases and dementias.Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice.
P2860
Q24291150-89BD47E8-E289-49CB-A60B-0A0CC7C0A83FQ24293089-87886ABF-A57F-4B20-A10E-C183C3D9961CQ24294532-1F303AB5-30EF-46FD-B693-59DAECFA405BQ24299289-1EFFBA71-FD23-4A75-B006-252648F0234EQ24311523-54EB48B1-616A-4B68-8952-9568A848109EQ24315670-B1261EA1-4A88-467E-B78D-4F99F651BEA0Q26269838-CF0ED016-E3E6-4F36-931D-0711156ED619Q26269886-1C9C0EEB-07AD-4A80-86A9-BA450A1743FAQ26269963-CD3C90C2-2A79-469E-8C7F-9AE009192313Q26823798-78672ED2-E058-49D0-9AC3-CD83F9E3F0A1Q26852964-0ECC0531-C4BE-47A0-86F2-B7087082116BQ27026292-1CDD18F2-53EF-419B-987D-F36C11A49C49Q27334018-46385F5E-DC4E-4C01-9D61-1D5DB4D0C3C2Q28141728-77DBA329-5D83-4516-8A1E-035B37C5352EQ28386471-3EDBE0EB-44C0-4DA3-BCB4-403BCE4BB70DQ28571838-4340575A-D86A-4CBF-85D8-462ADEA5D6EDQ28586519-2E1122B1-8B0A-4467-A799-5C4BB88F252BQ28591852-F734B88D-6F19-44A7-89B3-82B6F1A62E04Q28817941-F17C8AAD-CF73-4DF9-A459-2491C35671EEQ30405705-754895B3-7D1B-43FE-B9B8-4EBE4A50DA3EQ30427825-90E24A51-CA3E-479A-9358-371B2FCDF908Q30481396-57FAE46F-5863-4B29-B863-9B63F7EEE25EQ30493426-5BE7CE0E-A65C-4FE9-99D1-A92141B2BFB6Q30493813-A38A4385-AB0E-4361-B546-3AB1B8388236Q30500318-692741E2-89E6-4011-82B0-AEC90D803C74Q31165000-452DE431-82EA-4E26-B700-7C74AA09FA96Q33470625-54FB8C08-29CC-4ABE-B97A-381BEB05ACACQ33572030-2FE0733E-4A02-411A-9A52-4E822A6B8DF8Q33627226-BC0CEF91-96FA-4437-9033-A7C1448361EBQ33736637-DC366683-32FA-4EBD-AB2B-304F55B8C931Q33750063-672C292F-9264-4133-BD5E-F0DD1BF8207FQ33817178-06F8E631-D743-4C29-B406-F4AAD757D2B2Q33893738-0CDB53C7-CCE6-485D-9F05-F75EC7801ECEQ33929879-4B63DE6D-1EDA-474C-9E0A-96E823D1EBCEQ33947949-A7DABD5C-0090-4E1F-B4D6-F7B9538529D0Q33989372-A9E7A0F2-A790-4078-8C6B-ED1B7F346273Q33991720-24D0D84F-28D7-4939-9CB8-F11B664C9D24Q34107467-45C28AD9-A5DE-45FB-94EF-54CE04C1DE79Q34138249-50B990B1-51BD-4AEC-A84F-F607E55FD86EQ34263294-6DF613A5-4E16-4189-9848-13E556B24834
P2860
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@en
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@nl
type
label
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@en
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@nl
altLabel
Binding of α-Synuclein to Brai ...... l Parkinson’s Disease Mutation
@en
prefLabel
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@en
Binding of alpha-synuclein to ...... Parkinson's disease mutation.
@nl
P2093
P2860
P356
P1476
Binding of alpha-synuclein to ...... l Parkinson's disease mutation
@en
P2093
P2860
P304
26292-26294
P356
10.1074/JBC.273.41.26292
P407
P577
1998-10-01T00:00:00Z